IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
IDEAYA Biosciences (IDYA) reported updated Phase 1 results for IDE849, its DLL3-targeting ADC, at ESMO 2026. The study showed promising anti-tumor activity and preliminary overall survival in relapsed SCLC and NECs, with median OS of 17.4 months in 2L SCLC and 14.7 months in 2L + ≥3L SCLC. IDEAYA plans to initiate Phase 3 trials for ES-SCLC and NEC, targeting initiation following successful FDA meetings.
How this was made
The 30-second read
Why it matters
The disclosed median OS of 17.4 months in 2L SCLC and high ORR rates represent a strong efficacy signal for a first‑in‑class ADC, likely prompting a re‑rating by analysts.
Market read
First‑time disclosure of pivotal efficacy data for IDE849, a catalyst for IDYA and potentially the broader ADC market.
What to watch
Potential regulatory hurdles and the need for Phase 3 confirmation could delay commercial impact.
Background
Press release from IDEAYA Biosciences announcing Phase 1 update presented at ESMO 2026, including efficacy and safety metrics.
Ticker impact
IDEAYA Biosciences released updated Phase 1 data for its ADC IDE849 showing strong response rates and median overall survival in relapsed SCLC and neuroendocrine carcinomas.
likely upside as investors price in the encouraging efficacy and survival data.
The data are the first public disclosure of median OS and ORR for IDE849, a material catalyst for a biotech with no prior results, driving immediate market reaction.
Market effects
strengthens the ADC and DLL3‑targeted therapy space, may boost peer biotech valuations.
US biotech sector may see modest gains; Chinese partner Hengrui could see increased interest.
adds optimism to global oncology pipeline investors.
Counterpoint
Early‑stage data may be over‑hyped; safety signals and limited patient numbers could temper long‑term upside.
Key entities
- companyIDEAYA Biosciences, Inc.
Nasdaq‑listed biotech developing IDE849 ADC.
- companyJiangsu Hengrui Pharmaceuticals Co., Ltd.
Chinese partner presenting the China Phase 1 data.
